Kevin C. O'COnnor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kevin C. O'COnnor has a total of 524 co-authors. Here are the top co-authors by number of shared publications:
Richard J. Nowak
Yale School of Medicine
25 shared publications- Richard J. Nowak
Department of Neurology, Yale School of Medicine, New Haven, CT
14 shared publications - Miriam L. Fichtner
Department of Neurology with Experimental Neurology Charité Universitätsmedizin Berlin Berlin Germany
12 shared publications - Steven H. Kleinstein
Yale School of Medicine, New Haven, USA
12 shared publications - Minh Chau Pham
Department of Immunobiology, Yale University School of Medicine, New Haven, USA
11 shared publications Panos Stathopoulos
Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520, USA
10 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (6)
Detection of MOG-IgG and MOG-IgA in Maternal Breast Milk and Infant Blood in MOGAD
- 1 November 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (6)
Detection of MOG-IgG and MOG-IgA in Maternal Breast Milk and Infant Blood in MOGAD
- Open Access
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8730
Bispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder mediated by autoantibodies targeting the nicotinic acetylcholine receptor (nAChR), which can lead to severe disability and life-threatening crises. Current therapies rely on broad immunosuppression and fail to achieve sustained remission in the majority of patients. Here, we report the development of AChR chimeric autoantibody receptor (CAAR) T cells engineered to selectively eliminate autoreactive B cells producing anti-AChR autoantibodies. T cells were co-transduced with CAARs expressing extracellular domains of the AChRα1 or β1 subunits, enabling recognition of a broad range of pathogenic antibodies. AChR CAAR T cells selectively secreted effector cytokines upon activation, and efficiently lysed target cells. In a xenograft mouse model, they depleted pathogenic B cell lines and reduced autoantibody levels in the circulation and at the neuromuscular junction. These findings establish AChR CAAR T cells as a precision immunotherapy with the potential to achieve durable remission in refractory MG.
- 20 August 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 8730
Open AccessBispecific chimeric autoantibody receptor T cells eliminate acetylcholine receptor-specific B cells in myasthenia gravis models
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder mediated by autoantibodies targeting the nicotinic acetylcholine receptor (nAChR), which can lead to severe disability and life-threatening crises. Current therapies rely on broad immunosuppression and fail to achieve sustained remission in the majority of patients. Here, we report the development of AChR chimeric autoantibody receptor (CAAR) T cells engineered to selectively eliminate autoreactive B cells producing anti-AChR autoantibodies. T cells were co-transduced with CAARs expressing extracellular domains of the AChRα1 or β1 subunits, enabling recognition of a broad range of pathogenic antibodies. AChR CAAR T cells selectively secreted effector cytokines upon activation, and efficiently lysed target cells. In a xenograft mouse model, they depleted pathogenic B cell lines and reduced autoantibody levels in the circulation and at the neuromuscular junction. These findings establish AChR CAAR T cells as a precision immunotherapy with the potential to achieve durable remission in refractory MG.
- Open Access
Intrathecal antibodies cross-react with EBV BRRF2 and human antigens in multiple sclerosis
Intrathecal antibody synthesis is a hallmark of multiple sclerosis (MS). Although some intrathecally synthesized antibodies in MS are known to target viral antigens, the spectrum of their antigenic specificities remains incompletely defined. We combined proteome-wide antibody profiling by Phage ImmunoPrecipitation Sequencing (PhIP-Seq) with cross-compartment analytics (MICAR) to study intrathecal antibody synthesis at peptide resolution in paired CSF and serum samples from individuals with MS (n = 40) and non-MS controls (n = 83). While intrathecal antibody responses in MS were polyspecific and included reactivities to various viruses, we identified a subset of individuals with a convergent intrathecal antibody reactivity to a previously described motif within the Epstein-Barr virus (EBV) protein BRRF2 (BRRF2 408–415 ). This motif-directed response showed co-reactivity with multiple CNS-expressed human antigens. In an independent cohort of n = 909 individuals with MS and n = 311 controls, including individuals with NMOSD and MOGAD, serum antibodies to BRRF2 408–415 were detected in 8.36% of MS individuals and in 0.64% of non-MS controls, corresponding to an odds ratio for MS of 14.1 (95% CI: 4.4–86.04). Within MS individuals, BRRF2 408–415 seropositivity was associated with increased intrathecal IgG synthesis. Cross-reactivity of antibodies to BRRF2 408–415 with human targets, including TRIM71 and RTN2, was confirmed by competition ELISA and cell-based assays. Together, these data define an intrathecal EBV BRRF2-linked antibody signature with human target cross-reactivity in a subset of MS individuals. This signature identifies a highly specific serological marker in MS and may support future stratification of the heterogeneous MS spectrum.
Open AccessIntrathecal antibodies cross-react with EBV BRRF2 and human antigens in multiple sclerosis
Intrathecal antibody synthesis is a hallmark of multiple sclerosis (MS). Although some intrathecally synthesized antibodies in MS are known to target viral antigens, the spectrum of their antigenic specificities remains incompletely defined. We combined proteome-wide antibody profiling by Phage ImmunoPrecipitation Sequencing (PhIP-Seq) with cross-compartment analytics (MICAR) to study intrathecal antibody synthesis at peptide resolution in paired CSF and serum samples from individuals with MS (n = 40) and non-MS controls (n = 83). While intrathecal antibody responses in MS were polyspecific and included reactivities to various viruses, we identified a subset of individuals with a convergent intrathecal antibody reactivity to a previously described motif within the Epstein-Barr virus (EBV) protein BRRF2 (BRRF2 408–415 ). This motif-directed response showed co-reactivity with multiple CNS-expressed human antigens. In an independent cohort of n = 909 individuals with MS and n = 311 controls, including individuals with NMOSD and MOGAD, serum antibodies to BRRF2 408–415 were detected in 8.36% of MS individuals and in 0.64% of non-MS controls, corresponding to an odds ratio for MS of 14.1 (95% CI: 4.4–86.04). Within MS individuals, BRRF2 408–415 seropositivity was associated with increased intrathecal IgG synthesis. Cross-reactivity of antibodies to BRRF2 408–415 with human targets, including TRIM71 and RTN2, was confirmed by competition ELISA and cell-based assays. Together, these data define an intrathecal EBV BRRF2-linked antibody signature with human target cross-reactivity in a subset of MS individuals. This signature identifies a highly specific serological marker in MS and may support future stratification of the heterogeneous MS spectrum.
- Open Access
- 4 June 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (10) , 923-935
Pathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod
Background: Efgartigimod, a neonatal Fc receptor (FcRn) blocker, effectively reduces total IgG, including pathogenic acetylcholine receptor (AChR) autoantibodies in myasthenia gravis (MG); however, clinical responses vary. To investigate this variability, we studied how efgartigimod impacts AChR-specific autoantibody profiles and associated pathogenic mechanisms, including complement activation, AChR internalisation and ACh-binding site blockade. Methods: Serum samples (N=150) were sourced from 50 AChR autoantibody-positive generalised MG patients participating in the phase 3 ADAPT study, randomised to receive efgartigimod (N=40) or placebo (N=10) in cycles of 4-weekly infusions. Samples were collected at baseline, day 29 and day 57 during the first cycle. Live cell-based assays quantified AChR-specific IgG subclasses and isotypes and assessed their capacity to mediate pathomechanisms. Results: Efgartigimod decreased all detectable AChR-specific IgG subclasses. At baseline, AChR autoantibody-mediated C3b deposition, AChR internalisation and ACh-binding site blockade were detected in 42 (84%), 41 (82%) and 10 (20%) patients, respectively. After 4-weekly infusions of efgartigimod, the magnitude of all three pathomechanisms was significantly decreased. However, the extent of this reduction varied across individuals. Double responders on both MG-activities of daily living and quantitative MG scores demonstrated a greater reduction in complement activity and AChR internalisation compared with patients who responded on only one score or were double non-responders. In addition, efgartigimod reduced IgG-dependent IgM binding to AChR. Conclusions: These findings suggest that clinical efficacy may be more closely associated with functional modulation of the AChR-specific autoantibodies than with their absolute quantity alone. These results support the evaluation of mechanistic pathway monitoring as a potential strategy to predict or guide efgartigimod treatment response.
- 4 June 2026
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 97 (10) , 923-935
Open AccessPathogenic properties of myasthenia gravis AChR autoantibodies associate with clinical response to efgartigimod
Background: Efgartigimod, a neonatal Fc receptor (FcRn) blocker, effectively reduces total IgG, including pathogenic acetylcholine receptor (AChR) autoantibodies in myasthenia gravis (MG); however, clinical responses vary. To investigate this variability, we studied how efgartigimod impacts AChR-specific autoantibody profiles and associated pathogenic mechanisms, including complement activation, AChR internalisation and ACh-binding site blockade. Methods: Serum samples (N=150) were sourced from 50 AChR autoantibody-positive generalised MG patients participating in the phase 3 ADAPT study, randomised to receive efgartigimod (N=40) or placebo (N=10) in cycles of 4-weekly infusions. Samples were collected at baseline, day 29 and day 57 during the first cycle. Live cell-based assays quantified AChR-specific IgG subclasses and isotypes and assessed their capacity to mediate pathomechanisms. Results: Efgartigimod decreased all detectable AChR-specific IgG subclasses. At baseline, AChR autoantibody-mediated C3b deposition, AChR internalisation and ACh-binding site blockade were detected in 42 (84%), 41 (82%) and 10 (20%) patients, respectively. After 4-weekly infusions of efgartigimod, the magnitude of all three pathomechanisms was significantly decreased. However, the extent of this reduction varied across individuals. Double responders on both MG-activities of daily living and quantitative MG scores demonstrated a greater reduction in complement activity and AChR internalisation compared with patients who responded on only one score or were double non-responders. In addition, efgartigimod reduced IgG-dependent IgM binding to AChR. Conclusions: These findings suggest that clinical efficacy may be more closely associated with functional modulation of the AChR-specific autoantibodies than with their absolute quantity alone. These results support the evaluation of mechanistic pathway monitoring as a potential strategy to predict or guide efgartigimod treatment response.
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (3) , e200577
Generation of Monoclonal Autoantibodies From Myelin Oligodendrocyte Glycoprotein-Specific Human B Cells Using an Optofluidic-Based Platform
ObjectivesMonoclonal antibodies (mAbs) are powerful tools for elucidating disease mechanisms. Capturing heterogeneity of patient responses—including clonality, somatic mutations, isotypes, and path...
- 1 May 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (3) , e200577
Open AccessGeneration of Monoclonal Autoantibodies From Myelin Oligodendrocyte Glycoprotein-Specific Human B Cells Using an Optofluidic-Based Platform
ObjectivesMonoclonal antibodies (mAbs) are powerful tools for elucidating disease mechanisms. Capturing heterogeneity of patient responses—including clonality, somatic mutations, isotypes, and path...
- Open Access
- 20 March 2026
- Published by Springer Nature in Research Square
Engineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder caused by autoantibodies targeting the nicotinic acetylcholine receptor (nAChR), which can lead to severe disability and life-threatening crises. Current therapies rely on broad immunosuppression and fail to achieve sustained remission in the majority of patients. Here, we report the development of AChR chimeric autoantibody receptor (CAAR) T cells engineered to selectively eliminate autoreactive B cells producing anti-AChR autoantibodies. T cells were co-transduced with CAARs expressing extracellular domains of the AChR α1 or β1 subunits, enabling recognition of a broad range of pathogenic antibodies. AChR CAAR T cells selectively secreted effector cytokines upon activation, and efficiently lysed target cells. In vivo, they depleted pathogenic B cell lines and reduced autoantibody levels in the circulation and at the neuromuscular junction. These findings establish AChR CAAR T cells as a precision immunotherapy with the potential to achieve durable remission in refractory MG.
- 20 March 2026
- Published by Springer Nature in Research Square
Open AccessEngineered Bi-Specific AChR CAAR T Cells for Selective Elimination of Myasthenia Gravis B Cells
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder caused by autoantibodies targeting the nicotinic acetylcholine receptor (nAChR), which can lead to severe disability and life-threatening crises. Current therapies rely on broad immunosuppression and fail to achieve sustained remission in the majority of patients. Here, we report the development of AChR chimeric autoantibody receptor (CAAR) T cells engineered to selectively eliminate autoreactive B cells producing anti-AChR autoantibodies. T cells were co-transduced with CAARs expressing extracellular domains of the AChR α1 or β1 subunits, enabling recognition of a broad range of pathogenic antibodies. AChR CAAR T cells selectively secreted effector cytokines upon activation, and efficiently lysed target cells. In vivo, they depleted pathogenic B cell lines and reduced autoantibody levels in the circulation and at the neuromuscular junction. These findings establish AChR CAAR T cells as a precision immunotherapy with the potential to achieve durable remission in refractory MG.
- 13 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (117) , eaeg6827
IgG4 on the dance floor: Partners swapped by Fab-arm exchange
Proteomic analysis shows that nearly all circulating human IgG4 undergoes Fab-arm exchange, creating a vast bispecific antibody repertoire.
- 13 March 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (117) , eaeg6827
IgG4 on the dance floor: Partners swapped by Fab-arm exchange
Proteomic analysis shows that nearly all circulating human IgG4 undergoes Fab-arm exchange, creating a vast bispecific antibody repertoire.
- Open Access
Selective degradation of pathogenic autoantibodies by lysosomal targeting chimeras for the treatment of myasthenia gravis
Myasthenia gravis, an autoimmune disease characterized by muscle weakness that can manifest in bulbar dysfunction and respiratory distress, is driven in a subset of patients by autoantibodies against muscle-specific receptor tyrosine kinase (MuSK MG). MuSK MG and other autoantibody mediated disorders are generally treated with broad immunosuppressive approaches such as corticosteroids, plasmapheresis, B cell depletion, or FcRn inhibition, which can impact patient care via systemic side effects, variable responsiveness, and increased susceptibility to infection. We developed a lysosomal targeting chimera (LYTAC) therapeutic (MuSK LYTAC) that combines a MuSK antigen “Bait” capable of selectively binding to the disease-driving antibodies with asialoglycoprotein receptor (ASGPR) ligands that target the resulting immune complexes for degradation by ASGPR-expressing hepatocytes. Our optimized MuSK Bait effectively depleted pathogenic antibodies from the serum of 10 donors with MuSK MG, supporting broad applicability across the patient population. In vitro assays using both Hep G2 cells and primary human hepatocytes demonstrated that MuSK LYTAC is pharmacologically active, promoting uptake and lysosomal degradation of autoantibodies through an ASGPR-dependent mechanism. Mouse pharmacodynamic and passive immunization disease models showed that MuSK LYTAC rapidly eliminates autoantibodies from the serum and alleviates related disease symptoms, without impacting circulating IgG levels. These results support the promise of Autoantibody Bait LYTACs (ABLates) as precision treatments for MuSK MG and other autoantibody-driven diseases that avoid generalized immunosuppression.
Open AccessSelective degradation of pathogenic autoantibodies by lysosomal targeting chimeras for the treatment of myasthenia gravis
Myasthenia gravis, an autoimmune disease characterized by muscle weakness that can manifest in bulbar dysfunction and respiratory distress, is driven in a subset of patients by autoantibodies against muscle-specific receptor tyrosine kinase (MuSK MG). MuSK MG and other autoantibody mediated disorders are generally treated with broad immunosuppressive approaches such as corticosteroids, plasmapheresis, B cell depletion, or FcRn inhibition, which can impact patient care via systemic side effects, variable responsiveness, and increased susceptibility to infection. We developed a lysosomal targeting chimera (LYTAC) therapeutic (MuSK LYTAC) that combines a MuSK antigen “Bait” capable of selectively binding to the disease-driving antibodies with asialoglycoprotein receptor (ASGPR) ligands that target the resulting immune complexes for degradation by ASGPR-expressing hepatocytes. Our optimized MuSK Bait effectively depleted pathogenic antibodies from the serum of 10 donors with MuSK MG, supporting broad applicability across the patient population. In vitro assays using both Hep G2 cells and primary human hepatocytes demonstrated that MuSK LYTAC is pharmacologically active, promoting uptake and lysosomal degradation of autoantibodies through an ASGPR-dependent mechanism. Mouse pharmacodynamic and passive immunization disease models showed that MuSK LYTAC rapidly eliminates autoantibodies from the serum and alleviates related disease symptoms, without impacting circulating IgG levels. These results support the promise of Autoantibody Bait LYTACs (ABLates) as precision treatments for MuSK MG and other autoantibody-driven diseases that avoid generalized immunosuppression.
- 28 October 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (6) , 2091-2106
IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology
Patients with muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) develop muscle weakness due to functionally monovalent immunoglobulin (Ig) G4 autoantibodies (Abs) that target MuSK and disrupt acetylcholine receptor (AChR) clustering. Emerging evidence from other autoimmune conditions suggests that Abs of the IgA class—the archetypal immunoglobulin isotype at mucosal sites—may synergize with IgG Abs, contributing to pathology. In MuSK MG, however, the presence of disease-specific IgA Abs has not yet been recognized, limiting a broader understanding of IgG4-driven autoimmunity. To address this knowledge gap, we leveraged cell-based binding assays, patient-derived recombinant monoclonal autoantibodies (mAbs), high-throughput B-cell receptor sequencing, C2C12 mouse myotube cultures and passive immunization experiments. Among 112 sera collected from 25 patients with MuSK MG (discovery cohort), MuSK-specific IgA Abs were detected in eight samples, corresponding to 3/25 (12%) patients. This finding was validated in a second, independent cohort (validation cohort; n = 14 individuals), wherein one additional patient (1/14; 7.1%) harboured MuSK IgA Abs. Across all cases, MuSK IgA Abs coexisted with MuSK IgG Abs, while domain mapping demonstrated a polyclonal IgA response in 2/4 (50%) patients. Notably, in a paradigmatic case with longitudinal samples spanning over a decade, MuSK IgA seropositivity was persistent, and clonally expanded MuSK IgA B cells showed remarkable resistance to therapeutic B-cell depletion. We generated three patient-derived MuSK-specific IgA mAbs for in-depth molecular profiling. These mAbs were highly hypermutated, bound to distinct MuSK domains and shared target epitopes with MuSK IgG4 mAbs. Two IgA mAbs cross-reacted with murine MuSK, enabling functional studies with C2C12 myotubes. Mechanistically, individual IgA mAbs promoted AChR clustering (indicative of MuSK agonism) and partially antagonized the pathogenic effects of MuSK IgG4 monovalency. When modelling a polyclonal response, however, the combination of the same IgA mAbs significantly impaired cluster formation, demonstrating cooperative pathogenic potential. Consistent with this, passive transfer of both IgA clones into mice induced a myasthenic phenotype characterized by progressive weight loss, muscle weakness and structural disruption of the neuromuscular junction (effects similar to those elicited by a functionally monovalent MuSK IgG4 mAb). These findings uncover a previously unrecognized pathogenic Ab isotype in a subset of patients with MuSK MG and show a mechanism through which bivalent MuSK Abs may synergize to induce pathology. The identification of MuSK-specific IgA B cells could signal a role of mucosal or environmental factors in the pathogenesis of MuSK MG and other IgG4-mediated diseases, offering a worthy avenue for future research.
- 28 October 2025
- Published by Oxford University Press (OUP) in Brain
- Vol. 149 (6) , 2091-2106
IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology
Patients with muscle-specific tyrosine kinase (MuSK) myasthenia gravis (MG) develop muscle weakness due to functionally monovalent immunoglobulin (Ig) G4 autoantibodies (Abs) that target MuSK and disrupt acetylcholine receptor (AChR) clustering. Emerging evidence from other autoimmune conditions suggests that Abs of the IgA class—the archetypal immunoglobulin isotype at mucosal sites—may synergize with IgG Abs, contributing to pathology. In MuSK MG, however, the presence of disease-specific IgA Abs has not yet been recognized, limiting a broader understanding of IgG4-driven autoimmunity. To address this knowledge gap, we leveraged cell-based binding assays, patient-derived recombinant monoclonal autoantibodies (mAbs), high-throughput B-cell receptor sequencing, C2C12 mouse myotube cultures and passive immunization experiments. Among 112 sera collected from 25 patients with MuSK MG (discovery cohort), MuSK-specific IgA Abs were detected in eight samples, corresponding to 3/25 (12%) patients. This finding was validated in a second, independent cohort (validation cohort; n = 14 individuals), wherein one additional patient (1/14; 7.1%) harboured MuSK IgA Abs. Across all cases, MuSK IgA Abs coexisted with MuSK IgG Abs, while domain mapping demonstrated a polyclonal IgA response in 2/4 (50%) patients. Notably, in a paradigmatic case with longitudinal samples spanning over a decade, MuSK IgA seropositivity was persistent, and clonally expanded MuSK IgA B cells showed remarkable resistance to therapeutic B-cell depletion. We generated three patient-derived MuSK-specific IgA mAbs for in-depth molecular profiling. These mAbs were highly hypermutated, bound to distinct MuSK domains and shared target epitopes with MuSK IgG4 mAbs. Two IgA mAbs cross-reacted with murine MuSK, enabling functional studies with C2C12 myotubes. Mechanistically, individual IgA mAbs promoted AChR clustering (indicative of MuSK agonism) and partially antagonized the pathogenic effects of MuSK IgG4 monovalency. When modelling a polyclonal response, however, the combination of the same IgA mAbs significantly impaired cluster formation, demonstrating cooperative pathogenic potential. Consistent with this, passive transfer of both IgA clones into mice induced a myasthenic phenotype characterized by progressive weight loss, muscle weakness and structural disruption of the neuromuscular junction (effects similar to those elicited by a functionally monovalent MuSK IgG4 mAb). These findings uncover a previously unrecognized pathogenic Ab isotype in a subset of patients with MuSK MG and show a mechanism through which bivalent MuSK Abs may synergize to induce pathology. The identification of MuSK-specific IgA B cells could signal a role of mucosal or environmental factors in the pathogenesis of MuSK MG and other IgG4-mediated diseases, offering a worthy avenue for future research.
- Open Access
- 21 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (43)
Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology
Myasthenia gravis (MG) is an autoimmune disorder caused mainly by autoantibodies against the acetylcholine receptor (AChR), leading to muscle weakness. While treatments targeting AChR autoantibodies benefit many, some patients remain refractory, highlighting the need for personalized therapies. This study evaluates the therapeutic potential of S-1117, a pan-IgG-specific protease, in AChR autoantibody-mediated pathology. Using live cell-based assays, we examined AChR-specific monoclonal IgG autoantibodies (mAbs) and patient-derived serum samples for their effects on receptor binding, blockade, internalization, and complement activation, before and after treatment with S-1117. S-1117 effectively removed the crystallizable fragment (Fc)γ from both mAbs and serum IgG, impairing Fcγ-mediated complement activation in both soluble and antigen-bound forms. In cases with partial complement reduction, AChR-specific IgM contributed to complement deposition. AChR-IgM acted in concert with IgG in some patients to enhance complement deposition, while acting as main complement driver in others. An IgM-specific protease completely suppressed the pathogenic effects of AChR-IgM in two independent patient cohorts. These findings highlight the therapeutic potential of S-1117 in neutralizing AChR-IgG Fcγ-mediated effector functions and reveal an MG subset driven by IgM pathology. Our study shows that targeting both IgG- and IgM-mediated mechanisms with therapeutic proteases provides an approach to MG treatment and establishes a framework for patient stratification based on disease mechanisms, advancing precision medicine in MG.
- 21 October 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (43)
Open AccessTherapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology
Myasthenia gravis (MG) is an autoimmune disorder caused mainly by autoantibodies against the acetylcholine receptor (AChR), leading to muscle weakness. While treatments targeting AChR autoantibodies benefit many, some patients remain refractory, highlighting the need for personalized therapies. This study evaluates the therapeutic potential of S-1117, a pan-IgG-specific protease, in AChR autoantibody-mediated pathology. Using live cell-based assays, we examined AChR-specific monoclonal IgG autoantibodies (mAbs) and patient-derived serum samples for their effects on receptor binding, blockade, internalization, and complement activation, before and after treatment with S-1117. S-1117 effectively removed the crystallizable fragment (Fc)γ from both mAbs and serum IgG, impairing Fcγ-mediated complement activation in both soluble and antigen-bound forms. In cases with partial complement reduction, AChR-specific IgM contributed to complement deposition. AChR-IgM acted in concert with IgG in some patients to enhance complement deposition, while acting as main complement driver in others. An IgM-specific protease completely suppressed the pathogenic effects of AChR-IgM in two independent patient cohorts. These findings highlight the therapeutic potential of S-1117 in neutralizing AChR-IgG Fcγ-mediated effector functions and reveal an MG subset driven by IgM pathology. Our study shows that targeting both IgG- and IgM-mediated mechanisms with therapeutic proteases provides an approach to MG treatment and establishes a framework for patient stratification based on disease mechanisms, advancing precision medicine in MG.